Biotech Stocks Facing FDA Decision In March 2022

1 / 13

The FDA approved two novel drugs namely, Pyrukynd and Enjaymo, last month, bringing the total number of novel drug approvals so far this year to six.

Agios Pharma’s Pyrukynd is indicated to treat hemolytic anemia (a disorder in which red blood cells are destroyed faster than they can be made) in adults with pyruvate kinase deficiency.

Enjaymo, developed by Sanofi, is approved to decrease the need for red blood cell transfusion due to hemolysis in adults with cold agglutinin disease.